Bufotenine: Toward an Understanding of Possible Psychoactive Mechanisms
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
A review of the neuropharmacology of the alleged hallucinogen bufotenine is presented, including recent experimental results showing activity similar to LSD and other known hallucinogens (psilocin and 5-MeO-DMT) at the purported hallucinogenic serotonin (5-HT) receptors, 5-HT2A and 5-HT2C. In addition, current reports of computer modeling of the receptors and ligand binding sites give evidence of bufotenine's ability to bind and activate these receptors. While binding and activation of the purported hallucinogenic receptors are not the full extent of the hallucinogenic signature, this evidence shows support for the rationale that the reported lack of the drug's classic hallucinogenic response in human experiments is due to poor ability to cross the blood brain barrier (BBB), not lack of activation of the appropriate brain receptors. Further evidence is reviewed that in some physiological states, some drugs with characteristics similar to bufotenine which do not normally cross the BBB, cross it and enter the brain. While direct human experimental evidence of bufotenine's hallucinogenic activity seems lacking, the above combined factors are considered, and possible explanations of bufotenine's reported psychoactivity are suggested. Additionally, updated experimental models testing the possible nature of bufotenine's hallucinogenic potential are proposed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is not always the case; the low octanol:water partition coefficient for bufotenine (10) and the predicted low permeability to the blood–brain barrier, has been invoked to explain its relatively low hallucinogenic potency, despite moderate activity in serotonin receptor functional assays [146].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [146]
Citations
Cites
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Textbook of Medical Physiology
Iatridis, P. G. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470200123049 · Cited by 1,275
Psychopharmacology: The Fourth Generation of Progress
Green, A. I. (1996) · Psychiatric Services · doi:10.1176/ps.47.3.312 · Cited by 1,145
Remington's pharmaceutical sciences
(1976) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600650641 · Cited by 1,136
Lipcsey, A. (1980) · PubMed · Cited by 1,083
IVERSEN, L. L. (1971) · Nature New Biology · doi:10.1038/newbio229063c0 · Cited by 810
(1994) · Pharmaceutical Design And Development · doi:10.1201/b12597-9 · Cited by 784
Goodman and Gillman's The Pharmacological Basis of Therapeutics
Bigby, J. A. (1992) · Archives of Dermatology · doi:10.1001/archderm.1992.01680110146030 · Cited by 507
Research works printed but not linked: 11
- Aghajanian G. K., 1975, Psychopharmacology Communication, 619
- Borne R. F., 1994, Drug Topics, 108
- Coe M., 1980, In the Land of the Olmec.
- Donnelly D., 1994, Receptor Channels, 2, 61
- Huang K. N., 1991, Serotonin Receptor Subtypes: Basic and Clinical Aspects.
- Jacob P., 1994, Hallucinogens: An Update.
- Peroutka S. J., 1991, Serotonin Receptor Subtypes: Basic and Clinical Aspects.
- Sanders-Bush E., 1994, Hallucinogens: An Update.
- Schultes R. E., 1990, Flesh of the Gods, The Ritual Use of Hallucinogens.
- Shih J. C., 1995, Psychopharmacology: The Fourth Generation of Progress.
- Wasson R. G., 1990, Flesh of the Gods, The Ritual Use of Hallucinogens
Cited by
Schmid, C. L., & Bohn, L. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1665-10.2010 · Cited by 175
“In the brain, serotonin is a substrate for N-methyltransferases, enzymes that act to convert serotonin to N-methyltryptamines; these metabolites possess psychoactive properties and can be hallucinogenic in humans (Axelrod, 1962; Glennon and Gessner, 1979; Shulgin and Shulgin, 1997; McBride, 2000).”
BackgroundShen, H.-W., Jiang, X.-L., C. Winter, J., & Yu, A.-M. (2010) · Current Drug Metabolism · doi:10.2174/138920010794233495 · Cited by 170
“Bufotenine exhibits about 5- to 10-fold higher affinity to the 5-HT2A receptor than 5-MeO-DMT in vitro, and about 3-fold higher potency than 5MeO-DMT when they are present at similar level in brain [31, 77, 78].”
Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment
Brierley, D. I., & Davidson, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.001 · Cited by 156
Reckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15587 · Cited by 134
“The latter binds with a higher affinity to the 5- HT2A receptor than 5- MeO- DMT (Glennon et al., 1994; McBride, 2000; McKenna & Peroutka, 1989; Spencer et al., 1987) and also displays a high affinity for the 5- HT1A receptor (Hamon et al., 1986).”
BackgroundPolymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates
Yu, A., Idle, J. R., & Gonzalez, F. J. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120034000 · Cited by 122
“Its CYP2D6-mediated metabolite bufotenine is also psychotropic with a pharmacology that resembles that of lysergic acid diethylamide, psilocin, and its parent molecule 5-MDMT, which is believed to involve 5-HT2A and 5-HT2C receptors (McBride, 2000; Ott, 2001).”
Background
Metadata
- Authors
- McBride, M. C.
- Affiliations
- a Independent Researcher , Plano, Texas
- Corresponding author
- McBride, Michael C.
- Venue
- Journal of Psychoactive Drugs
- Publisher
- Informa UK Limited
- Published
- 2000-09-01
- Volume
- 32
- Issue
- 3
- Pages
- 321-331
- ISSN
- 0279-1072 (ISSN-L)
- 2159-9777
- OpenAlex
- W2055011448
- Cited by
- 74
- References
- 77
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 10 · 2022: 4 · 2021: 5 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 2 · 2015: 3 · 2013: 4 · 2012: 1
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychoactive Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Keywords
- bufotenine, hallucinogens, 5-HT2A receptor, 5-HT2C receptor, serotonin receptors, receptor binding, blood-brain barrier permeability, LSD, psilocin, 5-MeO-DMT
- MeSH terms
- Blood-Brain Barrier, Bufotenin, Humans, Psychotropic Drugs, Receptors, Serotonin, Serotonin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bufotenine: Toward an Understanding of Possible Psychoactive Mechanisms. https://app.cochat.ai/papers/10.1080/02791072.2000.10400456
- The paper
- McBride, M. C. (2000). Bufotenine: Toward an Understanding of Possible Psychoactive Mechanisms. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2000.10400456
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.